JudahBenHur
07 Nov 2016
Re: IPO back on Any more news?
penhome
06 Nov 2016
IPO back on IPO pricing back on for this coming week. How could the timing of this be worse?[link]
heinro
03 Nov 2016
Last one out turn off the lights! I cannot bear companies that try to cover up really bad news such as no money by trying to gloss over it or mask it by releasing two other RNS's at the same time which would appear to be good news.No money - no business, no company
penhome
01 Nov 2016
Updated SEC filings [link]
penhome
31 Oct 2016
Article on FierceBiotech today Commenting on this morning's RNS[link]
Elster
14 Oct 2016
NASDAQ ? Monday Morning?
penhome
14 Oct 2016
More filings More SEC filings yesterday relating to NASDAQ IPO and European placement:[link]
penhome
08 Sep 2016
Re: Motif on NASDAQ after all? Rumoured to be about to have another go at the NASDAQ combined with a European offering in a concurrent private placement. No RNS to this effect yet but draft SEC filing papers were published on LSE by 'Sellonews' this morning through this link:[link] sorting out the promissory notes share liability is part of the tidying up process?
Elster
08 Sep 2016
REVIVE 1 QUICK 3 RNS`S today. Skin Phase III enrollment ahead of plan : results Q2 17 instead of 2nd half 17
Elster
08 Sep 2016
Motif on NASDAQ after all? The2nd RNS about Amphion? atc suggests that motif will pay for photocopying and coffee at a rate of 15,000 pounds a month once they are listed on NASDAQ.Did I understand that right?This Amphibious motif owner smells a bit fishy. Running out of money?
JudahBenHur
26 Aug 2016
Chief Medical Officer presents at congress in USA Not on iii yet.[link] Medical Officer to present at the World Anti-Microbial Resistance Congress Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that Dr. David Huang, Chief Medical Officer, will lead a panel discussion at the World Anti-Microbial Resistance Congress in Washington, USA on 9 September 2016. The discussion is titled: 'In-licensing: Addressing the deficiencies in the original development program to develop a unique non-combination anti-infective'
onedb1
19 Aug 2016
Re: So as per my 27/04 post am still Long No change . The listing seems inevitable to me , just a little contrived. But once it comes it will gap the valuation with some of its Nasdaq peers Just hope they don't mess around for too long , Ie I want the listing fairly soon given what Penhome pointed out that the conditions are good
Sambram
16 Aug 2016
Big R&D cash burn, brokers seem positive "Motif’s H1 cash burn was broadly in line with our full year forecast.We expect the group’s cash burn to pick up in the second half as the company continues enrolling and dosing patients in two global Phase 3 clinical trials with an intravenous (IV)formulation of iclaprim, for thetreatment of ABSSSI. Data from the two trials are expected in the second half of 2017. The Company remains in registration with the US Securities and Exchange Commission and is continuing to engage with investors in anticipation of a NASDAQ listing." - Northland Capital"This morning the company reported its Interim results for the 6 months ended June 30th, 2016, with a cash balance of $19.5m. Motif’s lead drug candidate, iclaprim, is in phase III clinical trials in patients being treated for serious and life threatening bacterial infections, particularly those caused by drug resistant bacteria. Iclaprim is a next-generation antibiotic which targets an under-utilised mechanism of action, causing rapid killing of bacteria and making it an attractive candidate for acute infections caused by antibiotic-resistant species. The iclaprim phase III clinical trials (REVIVE 1 and 2) are progressing well with patient enrolment ahead of schedule." - Zeus Capital Taken from Research Tree
g austin
10 Aug 2016
Sold up Sold out for breakeven having held since 13 July. Reasons for selling were- Fiasco of deferring the Nasdaq listing and citing "market conditions"- Fact that the company's web site and RNS's provide no telephone number for the company - I hate companies that lurk in the shadow
Ripley94
10 Aug 2016
Re: Motif bio very volatile not at year low despite bad news. 19 /02 /16 josh for what that's worth. one of SP...TW... tips but he stated yesterday "brave to pile in"
